Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
6 000 women over a three-year period. Other cutting-edge<br />
techniques and technologies will be used in the project over<br />
time, and tumour and blood samples donated by patients<br />
will create an invaluable resource for further research that<br />
will help us to better understand and treat breast cancer.<br />
Expected results<br />
The TRANSBIG partners believe that the results of MIND-<br />
ACT will show that using the new technology to assess risk<br />
will result in fewer women being treated unnecessarily. This,<br />
in turn, will mean that fewer women will suff er from the<br />
unpleasant side-eff ects of chemotherapy. Not only will the<br />
overall quality of life of breast cancer patients be improved,<br />
but the healthcare costs associated with such cancer treatment<br />
will be reduced as well, thus providing a signifi cant<br />
benefi t to society. As the fi rst project in TRANSBIG, MIND-<br />
ACT will also establish valuable resources for future research<br />
and establish links between research and biotechnology<br />
enterprises in order to develop further diagnostic tools that<br />
can be widely disseminated and easily used by scientists<br />
and physicians alike.<br />
Potential applications<br />
The long-term aim is to develop TRANSBIG into a permanent<br />
network for translational research that is complementary to<br />
the clinical work done by BIG. This guarantees a connection<br />
between what scientists learn in the laboratory and what<br />
physicians and patients decide together about treatments<br />
in the clinic. But TRANSBIG’s reach will be wider than simply<br />
research. It will also be concerned with education through<br />
the provision of traineeships for young scientists and physicians,<br />
and public education on the issues involved with<br />
genomics by working closely together with cancer societies<br />
and patient advocacy groups. By bringing together scientists,<br />
clinicians, and representatives from patient groups,<br />
cancer societies and industry, TRANSBIG will bring a coherence<br />
and synergy to breast cancer research that has<br />
previously not existed in Europe.<br />
TREATMENT<br />
Coordinator<br />
Martine Piccart<br />
Breast International Group (BIG-aisbl)<br />
Brussels, Belgium<br />
transbig@bordet.be<br />
Partners<br />
Christos Sotiriou<br />
Institut Jules Bordet<br />
Brussels, Belgium<br />
Harry Bartelink<br />
The Netherlands <strong>Cancer</strong> Institute<br />
Amsterdam, The Netherlands<br />
Giuseppe Viale<br />
IEO – European Institute of Oncology<br />
Milan, Italy<br />
Jonas Bergh<br />
Karolinska Institute & Hospital<br />
Stockholm, Sweden<br />
Robert C.F. Leonard<br />
Géraldine A. Thomas<br />
Imperial College<br />
London, United Kingdom<br />
Denis Lacombe<br />
The European Organization for the<br />
<strong>Research</strong> and Treatment of <strong>Cancer</strong> (EORTC)<br />
Brussels, Belgium<br />
John Bartlett<br />
The University of Edinburgh<br />
Edinburgh, United Kingdom<br />
Michael Gnant<br />
Vienna General Hospital<br />
Vienna, Austria<br />
Alejandro Corvalan<br />
Chilean Cooperative Group<br />
for Oncologic <strong>Research</strong><br />
Santiago, Chile<br />
Adamos Adamou<br />
The Bank of Cyprus Oncology Centre<br />
Nicosia, Cyprus<br />
Lubos Petruzelka<br />
Dept. of Oncology of the 1 st Faculty of Medicine<br />
Charles University and General<br />
Teaching Hospital<br />
Prague, Czech Republic<br />
Henning Mouridsen<br />
Finsen Centre – Rigshopitalet<br />
Copenhagen, Denmark<br />
Mahasti Saghatchian-d’Assignies<br />
Suzette Delaloge<br />
Institut Gustave Roussy<br />
Villejuif, France<br />
Frank Wermer<br />
West German Study Group<br />
Frauenklinik der Heinrich-Heine-Universität<br />
Düsseldorf, Germany<br />
Gunter von Minckwitz<br />
Universitätsfrauenklinik<br />
Frankfurt, Germany<br />
Nadia Harbeck<br />
Technische Universitaet München<br />
Munich, Germany<br />
Christoph Thomssen<br />
Martin Luther Universität Halle Wittenberg<br />
Halle, Germany<br />
Christos Markopoulos<br />
National and Kapodistrian University<br />
of Athens<br />
Athens Medical School<br />
Athens, Greece<br />
Arnold Hill<br />
St. Vincent’s Hospital<br />
Dublin, Ireland<br />
Rodolfo Passalacqua<br />
Gruppo Oncologico Italiano<br />
di Ricerca Clinica<br />
Parma, Italy<br />
Caroline Duhem<br />
Centre Hospitalier de Luxembourg<br />
Luxembourg<br />
223
Change language